tradingkey.logo
tradingkey.logo
Search

Evotec to receive $100 mln as Gilead acquires Tubulis

ReutersApr 7, 2026 1:02 PM

- German biotech company Evotec EVTG.DE is to receive around $100 million upfront following the closing of the sale of private Germany-based Tubulis to Gilead, the company said on Tuesday.

Gilead GILD.O said it would acquire Tubulis for up to $5 billion, as the U.S. drugmaker looks to boost its pipeline with a lucrative class of experimental cancer drugs.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI